|
| LncRNAs | Pathways (genes involved with pathways) |
|
| H19 | Lysine degradation (KMT2D; SETD1B; KMT2B; SETD1A)
Ras signaling pathway (SYNGAP1; IGF2; KSR2; GNB5; GRIN2B)
IL-17 signaling pathway (MUC5B; MUC5AC)
Circadian entrainment (GNB5; GRIN2B) |
| NEAT1 | Lysine degradation (KMT2D; SETD1B; SETD1A)
Circadian entrainment (KCNJ6; GNB5; GRIN2B)
Ras signaling pathway (SYNGAP1; IGF2; KSR2; GNB5; GRIN2B)
Dopaminergic synapse (KCNJ6; GNB5; GRIN2B)
Maturity onset diabetes of the young (PDX1)
Peroxisome (MLYCD; PEX26) |
| MEG3 | GABAergic synapse (GABBR1; GAD2; CACNA1F)
Beta-alanine metabolism (GAD2; MLYCD)
GnRH secretion (GABBR1; CACNA1F)
Arrhythmogenic right ventricular cardiomyopathy (CACNG8; CACNA1F)
Taurine and hypotaurine metabolism (GAD2) |
| HULC | Ras signaling pathway (FGF17; SYNGAP1; GNB5; GNG13)
Retrograde endocannabinoid signaling (NDUFA10; GNB5; GNG13)
Gastric cancer (FGF17; MUC2; WNT7B) |
| FTX | Herpes simplex virus 1 infection (ZNF891; ZNF383; ZNF382; ZNF8; ZNF587; ZNF26; ZNF850)
Chagas disease (SMAD2; GNAI3; CFLAR)
Bladder cancer (RPS6KA5; MDM2)
Glycosaminoglycan biosynthesis (CHST12; ST3GAL2)
Signaling pathways regulating pluripotency of stem cells (SMAD2; NANOG; BMPR1A)
Hippo signaling pathway (SMAD2; WTIP; BMPR1A)
p53 signaling pathway (MDM2; MDM4) |
| MALAT1 | IL-17 signaling pathway (MUC5B; MUC5AC)
Ras signaling pathway (SYNGAP1; KSR2; GNB5) |
| MAYA | Beta-alanine metabolism (GAD2; MLYCD)
Focal adhesion (MYL5; RAP1A; PARVG; ITGA2)
Leukocyte transendothelial migration (MYL5; RAP1A; MAPK13)
Regulation of actin cytoskeleton (NCKAP1; MYL5; ABI2; ITGA2)
Platelet activation (RAP1A; ITGA2; MAPK13)
Ras signaling pathway (SYNGAP1; RAP1A; IGF2; REL)
Cellular senescence (CDKN2A; IPK2; MAPK13)
Taurine and hypotaurine metabolism (GAD2) |
| AC012668 | Spinocerebellar ataxia (ATXN3; PSMD11; GRIN2B)
Huntington disease (PSMD11; POLR2A; SDHC; GRIN2B) |
| CCAT1 | Bladder cancer (CDKN2A; MDM2)
Cell cycle (SMAD2; CDKN2A; MDM2)
Cellular senescence (SMAD2; CDKN2A; MDM2)
Hepatocellular carcinoma (SMAD2; CDKN2A; IGF2)
Melanoma (CDKN2A; MDM2)
p53 signaling pathway (CDKN2A; DM2)
Glioma (CDKN2A; MDM2)
Chronic myeloid leukemia (CDKN2A; MDM2)
Pancreatic cancer (SMAD2; CDKN2A) |
| SNHG20 | Maturity onset diabetes of the young (HNF1A) |
| GM10804 | Phototransduction (SLC24A1; CNGB1)
Circadian entrainment (RYR1; GRIN2A; GRIN2B)
Nicotine addiction (GRIN2A; GRIN2B)
Glutamatergic synapse (GRIN2A; GRIN2B; SHANK1)
cAMP signaling pathway (GRIN2A; ATP2B4; GRIN2B; CNGB1)
Cocaine addiction (GRIN2A; GRIN2B)
Systemic lupus erythematosus (GRIN2A; CD80; GRIN2B)
Spinocerebellar ataxia (RYR1; GRIN2A; GRIN2B)
Long-term potentiation (GRIN2A; GRIN2B)
Amphetamine addiction (GRIN2A; GRIN2B) |
| GAS5 | Ras signaling pathway (SYNGAP1; IGF2; KSR2; GNB5)
Glycerolipid metabolism (GLYCTK; LIPG) |
| CTCFLOS | Cocaine addiction (GRIN2A; DLG4; GRIN2B)
Glutamatergic synapse (GRIN2A; DLG4; GRIN2B; SHANK1)
Nicotine addiction (GRIN2A; GRIN2B)
Systemic lupus erythematosus (GRIN2A; CD80; GRIN2B)
Long-term potentiation (GRIN2A; GRIN2B)
Amphetamine addiction (GRIN2A; GRIN2B) |
| RP11-484 N16.1 | Spliceosome (HNRNPA3; FUS; PRPF40B; HNRNPA1)
Amyotrophic lateral sclerosis (HNRNPA3; FUS; NEFM; HNRNPA1; GRIN2B)
Arrhythmogenic right ventricular cardiomyopathy (CACNG7; CACNG8) |
| PLATR4 | Gastric acid secretion (KCNJ15; MYLK4) |
|
